GlassScriptPhysician profile
Wesley Burke Calhoun
NPI 1174508659
$9,400.53
in general payments reported to CMS, 2019-2025
40 companies · $1,069 in 2025
The $1,069 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $863 · 2020: $473 · 2021: $1,002 · 2022: $1,237 · 2023: $891 · 2024: $3,865 · 2025: $1,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,114 · Travel and Lodging: $1,637 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,113.68 |
| Travel and Lodging | $1,637.03 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,782.03 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $988.78 | 2019-2025 | Farxiga, Lokelma, Evusheld |
| Amgen INC. | $722.56 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $566.91 | 2019-2024 | Jynarque |
| Aurinia Pharma U.S., INC. | $506.22 | 2021-2025 | Lupkynis |
| Veloxis Pharmaceuticals, INC. | $435.07 | 2019-2025 | Envarsus |
| Calliditas Therapeutics US INC. | $405.18 | 2022-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $373.67 | 2020-2025 | Benlysta, Jesduvroq |
| Vifor Pharma, INC. | $354.67 | 2019-2024 | Veltassa |
| Novartis Pharmaceuticals Corporation | $334.71 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $317.32 | 2020-2024 | Acthar |
| Travere Therapeutics, INC. | $293.58 | 2022-2025 | Thiola |
| Bayer Healthcare Pharmaceuticals INC. | $276.79 | 2021-2025 | |
| Cormedix INC. | $198.91 | 2024-2025 | Defencath, Defencath |
| Ani Pharmaceuticals, INC. | $189.21 | 2023-2025 | Purified Cortrophin Gel |
Show all 37 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Calhoun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.